Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 16/20 | 0.60 |
| ▸ | MAPK8 | P45983 | 7/20 | 0.58 |
| ▸ | MAPK11 | Q15759 | 3/20 | 0.56 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.56 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.56 |
| ▸ | RPS6KA4 | O75676 | 1/20 | 0.56 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.56 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.56 |
| ▸ | NLK | Q9UBE8 | 1/20 | 0.56 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.53 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2948895 | 1.00 | MAPK14 (0.60) | MAPK14MAPK8MAPK11MAPK9MAPK10 | |
| SCHEMBL2945869 | 1.00 | MAPK14 (0.60) | MAPK14MAPK8MAPK11MAPK9MAPK10 | |
| SCHEMBL2945865 | 1.00 | MAPK14 (0.60) | MAPK14MAPK8MAPK11MAPK9MAPK10 | |
| SCHEMBL2949776 | 1.00 | MAPK14 (0.60) | MAPK14MAPK8MAPK11MAPK9MAPK10 | |
| SCHEMBL2948131 | 0.95 | MAPK14 (0.59) | MAPK14MAPK8MAPK11MAPK9MAPK10 | |
| SCHEMBL2948133 | 0.95 | MAPK14 (0.59) | MAPK14MAPK8MAPK11MAPK9MAPK10 | |
| SCHEMBL14266295 | 0.93 | MAPK14 (0.56) | MAPK14MAPK8MAPK11MAPK9MAPK10 | |
| SCHEMBL2946606 | 0.93 | MAPK14 (0.60) | MAPK14MAPK8MAPK11MAPK9MAPK10 | |
| SCHEMBL2946598 | 0.93 | MAPK14 (0.60) | MAPK14MAPK8MAPK11MAPK9MAPK10 | |
| SCHEMBL2939723 | 0.91 | MAPK14 (0.65) | MAPK14MAPK8MAPK11MAPK9MAPK10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7348331-B2 | Hydroxyalkyl substituted pyrido-7-pyrimidin-7-ones | ROCHE PALO ALTO LLC (US) | 2008-03-25 | — | — | US | claimed |
| US-20050107408-A1 | Hydroxyalkyl substituted pyrido-7-pyrimidin-7-ones | ROCHE PALO ALTO LLC | 2005-05-19 | — | — | US | claimed |
| US-7750016-B2 | Hydroxyalkyl substituted pyrido-7-pyrimidin-7-ones | ROCHE PALO ALTO LLC (US) | 2010-07-06 | — | — | US | disclosed |
| US-7750016-B2 | Hydroxyalkyl substituted pyrido-7-pyrimidin-7-ones | ROCHE PALO ALTO LLC (US) | 2010-07-06 | — | — | US | disclosed |
| US-7750016-B2 | Hydroxyalkyl substituted pyrido-7-pyrimidin-7-ones | ROCHE PALO ALTO LLC (US) | 2010-07-06 | — | — | US | disclosed |
| US-20080119497-A1 | Hydroxyalkyl substituted pyrido-7-pyrimidin-7-ones | ROCHE PALO ALTO LLC | 2008-05-22 | — | — | US | disclosed |
| US-20080119497-A1 | Hydroxyalkyl substituted pyrido-7-pyrimidin-7-ones | ROCHE PALO ALTO LLC | 2008-05-22 | — | — | US | disclosed |
| US-20080119497-A1 | Hydroxyalkyl substituted pyrido-7-pyrimidin-7-ones | ROCHE PALO ALTO LLC | 2008-05-22 | — | — | US | disclosed |
| US-7348331-B2 | Hydroxyalkyl substituted pyrido-7-pyrimidin-7-ones | ROCHE PALO ALTO LLC (US) | 2008-03-25 | — | — | US | disclosed |
| US-7348331-B2 | Hydroxyalkyl substituted pyrido-7-pyrimidin-7-ones | ROCHE PALO ALTO LLC (US) | 2008-03-25 | — | — | US | disclosed |
| US-7348331-B2 | Hydroxyalkyl substituted pyrido-7-pyrimidin-7-ones | ROCHE PALO ALTO LLC (US) | 2008-03-25 | — | — | US | disclosed |
| EP-1685131-B1 | HYDROXYALKYL SUBSTITUTED PYRIDO-7-PYRIMIDIN-7-ONES | HOFFMANN LA ROCHE (CH) | 2007-03-07 | — | — | EP | disclosed |
| US-20050107408-A1 | Hydroxyalkyl substituted pyrido-7-pyrimidin-7-ones | ROCHE PALO ALTO LLC | 2005-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119497-A1 | Hydroxyalkyl substituted pyrido-7-pyrimidin-7-ones | MAPK1, MAPK7, MAPK6 | MAPK14 39/4885MAPK8 7/4885MAPK11 42/4885 |
| US-20050107408-A1 | Hydroxyalkyl substituted pyrido-7-pyrimidin-7-ones | MAPK1, MAPK7, MAPK6 | MAPK14 39/4885MAPK8 7/4885MAPK11 42/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.